ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS

Leading Companies

Global Onychomycosis Treatment Market: Key Developments

In April 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for JUBLIA (efinaconazole) topical solution, 10%, to treat onychomycosis, a fungal infection of the toenails.

In June 2019, Galderma SA, and the European Society for Dermatological Research (ESDR) and healthcare companies LEO Pharma and Celgene, joined forces to find the Skin Science Foundation (SSF) in Geneva, Switzerland. This will accelerate next generation skincare by using cutting-edge science to better understand skin health and its transition to disease.

Global Onychomycosis Treatment Market: Key Companies Insights

The global onychomycosis treatment market is highly competitive. This is attributed to the rise in demand for safe and effective treatment, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global onychomycosis treatment market are Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.